Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Investor Presentation (May 2011)
25 slides from Glenmark Pharmaceuticals's investor presentation, May 16, 2011
Slide 1: Biologics Developments
Glenmark Pharmaceuticals Ltd. BIOLOGICS DEVELOPMENTS May 16, 2011
Slide 2: Glenmark Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi
Glenmark Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi Sanofi to develop GBR 500 for Crohn’s Disease and other anti- inflammatory conditions such as Multiple Sclerosis Upfront payment of US$ 50 million • US$ 25 million will be paid upon closing of the transaction • US$ 25 million upon S
Slide 3: Glenmark Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi
Glenmark Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi Sanofi will have exclusive marketing rights for North America, Europe, Japan, Argentina, Chile and Uruguay Sanofi and Glenmark will co-market in Russia, Brazil, Australia and New Zealand Glenmark will retain exclusive marketing righ
Slide 4: Landmark Deal for Glenmark: The Firsts
Landmark Deal for Glenmark The Firsts First novel biologics out-licensing deal for Glenmark First novel biologics out-licensing deal from Indian company 4
Slide 5: Landmark Deal for Glenmark
Landmark Deal for Glenmark Validates Glenmark’s capabilities in Biologics arena - monoclonal antibodies - one of the largest and fastest growing segment within Biologics Glenmark recognized as one of the unique global mid-size pharma companies with presence across Novel Chemical Entities (NCE) as we
Slide 6: Glenmark Novel Drug Pipeline
Glenmark Novel Drug Pipeline Compound Primary Indication Target PC PI P II P III Mkt Crofelemer Anti-diarrheal CFTR Inhibitor GRC 4039 Asthma, COPD, Rheumatoid In-licensed from Napo Pharmaceuticals PDE IV Inhibitor (Revamilast) Arthritis Osteoarthritis Pain, TRPV-3 GRC 15300 Neuropathic Pain Antagon
Slide 7: Glenmark's Biologics R&D Pipeline and Capabilities: An Update
Glenmark’s Biologics R&D Pipeline and Capabilities : An Update Biologics Infrastructure Biologics Pipeline Technologies and Capabilities 7
Slide 8: Glenmark Biologics Infrastructure: GSA – La Chaux-de-Fonds
Glenmark Biologics Infrastucture : GSA – La Chaux-de-Fonds 8
Slide 9: Glenmark Pharmaceuticals SA
Glenmark Pharmaceuticals SA La Chaux-de-Fonds, Canton of Neuchâtel, Switzerland Biologics R&D center Labs 2006 55 scientists, staff from 12 nations R&D and process development Focus monoclonal antibody products 9
Slide 10: Antibody Capabilities
Formulation Immunology Antibody Eng Antibody Capabilities Cell Culture DSP NBE’s • From target to molecule • Process development USP QC/ Analytical Subsequent development (pre-clinical and clinical) through Glenmark’s common R&D resources in India, UK and US 10
Slide 11: Antibodies
Antibodies Antigen Antigen Antibody 11
Slide 12: Why Focus on Antibodies?
Why Focus on Antibodies? Antibodies Four out of 5 top selling drugs are antibodies Big pharma companies massively invest into antibodies >20 antibody products on the Exquisite target specificity market, several hundred in development Evolved by nature to bind with high specificity to a target Other
Slide 13: Glenmark Capabilities
Glenmark Capabilities “From target to antibody” Screening technologies Antibody engineering Antibody expression Antibody purification and formulation Platform technologies Own intellectual property or freedom to operate 13
Slide 14: GBR 500 Key Facts
GBR 500 Key Facts Monoclonal antibody, first in class Targets αI domain of human 2β1 integrin (VLA-2) Novel mechanism - Inhibits retention of inflammatory cells at site of inflammation Target expressed only during inflammation 14
Slide 15: GBR 500
GBR 500 Broad therapeutic spectrum; potential indications: - Crohn’s disease, inflammatory bowel disease - Multiple sclerosis - Potentially other inflammatory diseases - Potential to expand indications to oncology In-line with mechanism clean toxicological profile Phase I dosing completed - drug has
Slide 16: GBR 600 Key Facts
GBR 600 Key Facts Blood Flow Monoclonal antibody, first in class Platelet First step in Sub-nM potency platelet plug formation Targets the A1 domain of human van Willebrand Factor vWF) - Inhibits vWF mediated platelet aggregation - “Neutralises” overactive/over vWF binds collagen GPVI and 2ß1
Slide 17: GBR 600
GBR 600 Multiple indications “Neutralization” of overactive/over expressed vWF E.g. TTP (idiopathic thrombotic thrombocytopenic pupurea) Platelet inhibition E.g. acute coronary syndrome Differentiation from other platelet inhibitors Works in all individuals Works immediately No bleeding liability Ca
Slide 18: GBR401 - a better Rituximab
GBR401 - a better Rituximab Anti-CD19 antibody Deplete malignant/auto reactive B cells upon binding - Same proven concept as Rituximab, - but broader therapeutic spectrum and potential to overcome Rituximab resistance CD19 Expressed exclusively on normal and malignant B cells Broader expression than
Slide 19: GBR 401
GBR 401 Indications Initial focus oncology - B cell tumors Autoimmune diseases - Deplete B lymphocytes that produce auto-immune antibodies 19
Slide 20: GBR401 Status
GBR401 Status Monoclonal antibody directed against CD19, best in class potential Re-engineered to enhance killing properties Excellent results in animal models IND enabling studies ongoing 20
Slide 21: Platform technologies
Platform technologies Basis for Improved antibodies New antibody formats Examples Improved killing properties of antibodies Bi-specific antibodies High-yield expression of antibodies 21
Slide 22: Bi-Specific Antibodies
Bi-Specific Antibodies Standard antibody (e.g. IgG): Bi-specific antibody: Binds 2x to the same target Binds 1x to 2 different targets 22
Slide 23: Why Bi-Specific Antibodies?
Why Bi-Specific Antibodies? Highly specific multi-target drug - E.g. oncology Improve properties of antibody - Enhanced killing or no killing Improved therapy, more individuals can be treated Unique format, better patent protection 23
Slide 24: Glenmark Bi-Specific Antibody
Glenmark Bi-Specific Antibody Unique format - Intellectual property Very good assembly Good purification 24
Slide 25: 25
25
Glenmark Pharmaceuticals — Investor Presentation (May 2011) on 6ix